Department of Oncology, The Affiliated Hospital of Medical College, Qing Dao University, Quingdao, China.
Swiss Med Wkly. 2009 Dec 12;139(49-50):724-8. doi: 10.4414/smw.2009.12754.
To determine whether genetic polymorphisms of GSTP1 Ile105Val (A-->G) predict chemosensitivity and clinical outcome in patients with advanced colorectal cancer, treated by 5-FU/oxaliplatin-based chemotherapy.
In this retrospective study, the population consisted of 122 advanced colorectal cancer patients (III stage 51, IV stage 71). Patients were treated with 5-FU-oxaliplatin-based chemotherapy, and their response was evaluated after at least two cycles of treatments; all patients (122) were evaluated for median survival time (MST). GSTP1 genotypes were detected by TaqMan-MGB probe methods.
75 patients (61.47%) were Ile/Ile genotype, 10 (8.2%) were Val/Val genotype, and 37 (30.33%) were Ile/Val genotype. Patients possessing the glutathione S-transferase P1-105 Val/Val genotype showed a response rate of 60.0% compared to 25.89% in patients harboring at least one GSTP1-105 Ile allele (p = 0.032). GSTP1-105 Val/Val patients demonstrated a significant superior median survival time of 20.4 months (95% CI: 11.85 to 28.95) compared to 6.5 months (95% CI: 4.26 to 8.74) in patients with 105 Ile/Ile genotype and 10.3 months (95% CI: 7.05 to 13.55; p <0.01) in patients with GSTP1 105 Ile/Val genotype.
The GSTP1 105Val/105Val genotype is associated with a higher clinical response rate to oxaliplatin-based chemotherapy and with increased survival of patients with advanced colo-rectal cancer, receiving 5-FU/oxaliplatin chemotherapy.
确定 GSTP1 Ile105Val（A-->G）基因多态性是否可预测接受基于 5-FU/奥沙利铂的化疗的晚期结直肠癌患者的化疗敏感性和临床结局。
在这项回顾性研究中，人群由 122 例晚期结直肠癌患者（III 期 51 例，IV 期 71 例）组成。患者接受 5-FU-奥沙利铂为基础的化疗，至少两个周期治疗后评估其反应；所有患者（122 例）均评估中位生存时间（MST）。GSTP1 基因型采用 TaqMan-MGB 探针法检测。
75 例（61.47%）患者为 Ile/Ile 基因型，10 例（8.2%）患者为 Val/Val 基因型，37 例（30.33%）患者为 Ile/Val 基因型。携带谷胱甘肽 S-转移酶 P1-105 Val/Val 基因型的患者反应率为 60.0%，而至少携带一个 GSTP1-105 Ile 等位基因的患者反应率为 25.89%（p=0.032）。GSTP1-105 Val/Val 患者的中位生存时间明显优于 Ile/Ile 基因型患者（20.4 个月，95%CI：11.85 至 28.95）和 Ile/Val 基因型患者（10.3 个月，95%CI：7.05 至 13.55；p<0.01）。
GSTP1 105Val/105Val 基因型与接受基于奥沙利铂的化疗的晚期结直肠癌患者的更高临床反应率以及增加的生存相关，这些患者接受 5-FU/奥沙利铂化疗。
Zotero 插件